Developing MASH Therapeutics Utilizing Complex 3D Human In Vitro, In Vivo & Ex Vivo Models to Validate MASH Therapeutic Efficacy Across Systems

•  Identification and validation of targets in complex 3d in vitro human models of MASH
• Comparison of activity throughout development across the development cycle, and the value of complex 3D human cellular in vitro models to reduce translational risk
• Integrating human-relevant ex vivo systems into validation and drug development workflows to increase biological relevance, improving decision-making and accelerating candidate progression

Speakers:

Keith Murphy

CEO & Founder

Viscient Biosciences